Criticaleye recently caught up with Abbas Hussain, President, Emerging Markets at GlaxoSmithKline, to discuss the state of emerging markets and the initial stages of GSK’s low-cost drug plan, a revolutionary scheme set to change the face of the pharmaceutical industry.
Read, watch & listen to some of the latest thought leadership from our Community.
Focused on what leaders should be prioritising over the next twelve months, advice for first-time CEOs and how Chairs in high-growth businesses can better support their CEOs. Key discussion points include: Pr...
In the face of escalating societal demands, intensified stakeholder scrutiny and expanding global regulatory requirements, the pressure is on for businesses to assume their collective responsibility towards both people ...
Most economists are predicting higher volumes for M&A over the next 12 months, albeit coming off a low base. In this article, Criticaleye’s Jacob Ambrose Willson hears from Matthew Parker, CEO of the highly ac...
Displaying 1 to 3 of 1,666
We use cookies to improve your experience. By using our site, you agree to our use of cookies.
